Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1455-1461

  Abidi, Muneer H ^a,c   Agarwal, Rishi ^b   Ayash, Lois ^a,c   Deol, Abhinav ^a,c   Al Kadhimi, Zaid ^a,c   Abrams, Judith ^a,c   Cronin, Simon ^a   Ventimiglia, Marie ^a   Lum, Lawrence ^a,c   Zonder, Jeffrey ^a,c   Ratanatharathorn, Voravit ^a,c   Uberti, Joseph ^a,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b Synergy Medical Education Alliance   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Autologous stem cell transplant; High dose melphalan; Myeloma; Palifermin

Indexed keywords

CREATININE; MELPHALAN; PALIFERMIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE LIMITING TOXICITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TOXICITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NAUSEA; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; RASH; SIDE EFFECT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CREATININE; CYTOPROTECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RENAL INSUFFICIENCY, CHRONIC; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84865163334     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.03.010     Document Type: Article

References (30)

1. Knudsen L.M., Hjorth M., Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000, 65:175-181.
2. San Miguel J.F., Lahuerta J.J., García-Sanz R., et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J 2000, 1:28-36.
3. Sirohi B., Powles R., Kulkarni S., et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001, 85:325-332.
4. Tricot G., Alberts D.S., Johnson C., et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947-952.
5. Knudsen L.M., Nielsen B., Gimsing P., Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005, 75:27-33.
6. Kyle R.A., Rajkumar S.V. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009, 9:278-288.
7. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
8. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227-9233.
9. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
10. Bladé J., Rosiñol L., Cibeira M.T., Rovira M., Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010, 115:3655-3663.
11. Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 1995, 13:1786-1799.
12. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731-735.
13. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
14. Keefe D.M., Sonis S.T., Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 2008, 13:511-522.
15. Schuster M.W., Shore T.B., Harpel J.G., et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Support Care Cancer 2008, 16:477-483.
16. Spencer A., Horvath N., Gibson J., et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005, 35:971-977.
17. Phillips G.L., Meisenberg B., Reece D.E., et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004, 10:473-483.
18. Rubin J.S., Osada H., Finch P.W., Taylor W.G., Rudikoff S., Aaronson S.A. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 1989, 86:802-806.
19. Blijlevens N., Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007, 18:817-826.
20. Meropol N.J., Somer R.A., Gutheil J., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003, 21:1452-1458.
21. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351:2590-2598.
22. Booth D., Potten C.S. Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 2001, (29):16-20.
23. Kobbe G., Bruns I., Schroeder T., et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010, 21:1898-1904.
24. Grazziutti M.L., Dong L., Miceli M.H., et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006, 38:501-506.
25. Ruescher T.J., Sodeifi A., Scrivani S.J., et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998, 82:2275-2281.
26. Lark R.L., McNeil S.A., Vander Hyde K., et al. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001, 33:338-343.
27. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001, 19:2201-2205.
28. Blijlevens N.M., Donnelly J.P., De Pauw B.E. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for hematological malignancy: an overview. Bone Marrow Transplant 2000, 25:1269-1278.
29. Pierce G., Yanagihara D., Klopchin K., et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med 1994, 179:831-840.
30. Lilleby K., Garcia P., Gooley T., et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:1031-1035.